‌

US Patent 11547727 Chimeric antigen receptor-modified NK-92 cells

Patent 11547727 was granted and assigned to ImmunityBio on January, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Laurent H. Boissel0

Hans G. Klingemann0

Date of Patent

January 10, 2023

0

Patent Application Number

169691520

Date Filed

May 21, 2019

0

Patent Citations

US Patent 10138462 Natural killer cell lines and methods of use

Patent Citations Received

US Patent 11992504 Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

0

...

Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11547727 Chimeric antigen receptor-modified NK-92 cells

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.